An Interview with A Mentor- Dr. Robert Langer, Sc.D. (MIT Institute Professor) on aspects of the Future of Diabetes Medicine Research

<p>An Interview with A Mentor- Dr. Robert Langer, Sc.D. (MIT Institute Professor) on aspects of the Future of Diabetes Medicine Research</p><p>======</p><p>Diabetes therapy is entering a new phase. For decades, the central challenge was how to deliver insulin more safely, more intelligently, and more responsively. </p><p>The research work by Dr. Langer has produced a generation of technologies aimed at making therapy more autonomous: glucose-responsive insulin systems, microneedle patches, implantable rescue devices, lipid nanoparticles, and mRNA-based approaches to protein replacement.</p><p>At the same time, a separate revolution emerged from pharmacology. GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and now triple GIP/GLP-1/glucagon agonists have changed expectations for the treatment of type 2 diabetes and obesity. </p><p><br /></p><p>=====</p><p>Music by <a href="https://pixabay.com/users/kornevmusic-34073243/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=music&amp;utm_content=487426" rel="ugc noopener noreferrer" target="_blank">⁠ANDRII KORNIEV⁠</a> from <a href="https://pixabay.com/music//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=music&amp;utm_content=487426" rel="ugc noopener noreferrer" target="_blank">⁠Pixabay⁠</a></p><p>====</p><p><em>Views of this interview reflect those of my guest and I. They don't constitute medical or professional advice. We disclaim any loss in any way.</em></p><p><br /></p>